Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis

Phase 2 Completed 5 enrolled National Center for Research Resources (NCRR) Scripps Clinic · collab

Treatment

Summary

OBJECTIVES: I. Evaluate the effects of cladribine (2-chlorodeoxyadenosine; 2-CdA) on biochemical, radiologic, and histologic parameters in patients with early stage primary sclerosing cholangitis.

Timeline

Start: 1994-12
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cladribine	Small molecule	—	Subcutaneous

Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis

Summary

Timeline

Drugs

Indications